Advertisement

Picture EBD Group BioTech Showcase 2021 Digital Event BTS2021 651x81
Document › Details

Mondobiotech Holding AG. (11/25/11). "Press Release: MondoBiotech Holding AG (SIX: RARE) Sets Out to Clarify Some Statements Appearing in Today’s Press". Stans.

Region Region Switzerland
Organisations Organisation Mondobiotech Holding AG
  Today Relief Therapeutics Holding AG (SIX: RLF, OTCQB: RLFTF)
  Group Relief Therapeutics (Group)
  Organisation 2 BioPharma Invest AG
Product Product DRUGS, ORPHAN
     


Due to some unsubstantiated statements appearing in todays' press, the company sets out to clarify that there is no delay in the access to the loan facility received from its largest shareholder Biopharma Invest AG on 14th November 2011. As announced on that date, an austerity plan had been identified and was ready to be implemented at any time to further reduce the company's liquidity needs. In the press release dated 24th of November 2011, the company explained that it had decided to implement certain restructuring measures which were part of this austerity plan. These actions preserve the value of the company's core assets in the interim due to the current financial market conditions and the delay of significant progress with respect to fulfill fund raising activity.


About mondoBIOTECH

mondoBIOTECH holding AG (SIX Swiss Exchange ticker symbol: RARE), an independent Swiss biotech company, discovers drugs for patients suffering from rare diseases through its internally developed Search&Match methodology. In Search&Match mondoBIOTECH's scientists combine their unique knowledge of biologically active human peptides with advanced technology solutions delivering medicinal product candidates for rare diseases to licensing partners.

Furthermore, mondoBIOTECH has built and is expanding a continuously growing Community of high-level physicians and researchers who dedicate their life to rare diseases. This Rare Community is composed of biologists, biochemists, physicians, patients and patient advocacy organizations as well as other persons and organizations who share their experiences, know-how, expertise and skills with mondoBIOTECH to reach out to people who will benefit the most from an effective treatment, the patients.

For further information please contact

mondoBIOTECH holding AG
Maria Teresa D'Antonangelo Buehlmann
Das Kloster
Muergstrasse 18
CH-6370 Stans
Tel.: +41 (0) 840 200 010
Fax: +41 (0) 840 200 011
investor@mondobiotech.com
www.mondobiotech.com

Disclaimer
This communication expressly or implicitly contains certain forward-looking statements concerning mondoBIOTECH holding AG and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of mondoBIOTECH holding AG to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. mondoBIOTECH holding AG is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise.

   
Record changed: 2017-04-02

Advertisement

Picture ConsulTech GmbH RnD Credit Germany 650x80px

More documents for Relief Therapeutics (Group)


To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]

Advertisement

Picture EBD Group Digital Medicine & Medtech Showcase 2021 at BTS2021 651x81




» top